Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2006 2
2010 1
2011 1
2012 2
2013 5
2014 1
2015 6
2016 2
2019 6
2020 2
2021 5
2022 5
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
Risk stratification and medical therapy of pulmonary arterial hypertension.
Galiè N, Channick RN, Frantz RP, Grünig E, Jing ZC, Moiseeva O, Preston IR, Pulido T, Safdar Z, Tamura Y, McLaughlin VV. Galiè N, et al. Among authors: channick rn. Eur Respir J. 2019 Jan 24;53(1):1801889. doi: 10.1183/13993003.01889-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545971 Free PMC article. Review.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. Among authors: channick r. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. Pulido T, et al. Among authors: channick rn. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917. N Engl J Med. 2013. PMID: 23984728 Free article. Clinical Trial.
The REPAIR Study: Effects of Macitentan on RV Structure and Function in Pulmonary Arterial Hypertension.
Vonk Noordegraaf A, Channick R, Cottreel E, Kiely DG, Marcus JT, Martin N, Moiseeva O, Peacock A, Swift AJ, Tawakol A, Torbicki A, Rosenkranz S, Galiè N. Vonk Noordegraaf A, et al. Among authors: channick r. JACC Cardiovasc Imaging. 2022 Feb;15(2):240-253. doi: 10.1016/j.jcmg.2021.07.027. Epub 2021 Nov 17. JACC Cardiovasc Imaging. 2022. PMID: 34801462 Free article.

RESULTS: At a prespecified interim analysis in 42 patients, both primary endpoints were met, enrollment was stopped, and the study was declared positive. At final analysis (n = 71), RV stroke volume increased by 12 mL (96% confidence level: 8.4-15.6 mL; P < 0.0001) and

…
RESULTS: At a prespecified interim analysis in 42 patients, both primary endpoints were met, enrollment was stopped, and the study was decla …
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study.
Rosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, McLaughlin VV, Du Roure C, Rubin LJ, Sitbon O, Tapson V, Lang IM. Rosenkranz S, et al. Among authors: channick r. Eur J Heart Fail. 2022 Jan;24(1):205-214. doi: 10.1002/ejhf.2369. Epub 2021 Nov 21. Eur J Heart Fail. 2022. PMID: 34806261 Free PMC article. Clinical Trial.
These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study. METHODS AND RESULTS: Randomized patients (n = 1156) were classified using three methods: (i) by subgroups defined according to previously publis …
These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study. METHODS AND …
Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. McLaughlin VV, et al. Among authors: channick rn. J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027. J Am Coll Cardiol. 2010. PMID: 20430262 Free article. Clinical Trial.
Secondary end points included time to clinical worsening, Borg Dyspnea Score, NYHA functional class, 12-week trough 6MWD, 6-week peak 6MWD, quality of life, and PAH signs and symptoms. The biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP) was assessed. ...
Secondary end points included time to clinical worsening, Borg Dyspnea Score, NYHA functional class, 12-week trough 6MWD, 6-week peak 6MWD, …
Inhaled Treprostinil in Group 3 Pulmonary Hypertension.
Saggar R, Abtin F, Channick R. Saggar R, et al. Among authors: channick r. N Engl J Med. 2021 May 13;384(19):1870. doi: 10.1056/NEJMc2103465. N Engl J Med. 2021. PMID: 33979498 No abstract available.
Circulating NEDD9 is increased in pulmonary arterial hypertension: A multicenter, retrospective analysis.
Samokhin AO, Hsu S, Yu PB, Waxman AB, Alba GA, Wertheim BM, Hopkins CD, Bowman F, Channick RN, Nikolic I, Faria-Urbina M, Hassoun PM, Leopold JA, Tedford RJ, Ventetuolo CE, Leary PJ, Maron BA. Samokhin AO, et al. Among authors: channick rn. J Heart Lung Transplant. 2020 Apr;39(4):289-299. doi: 10.1016/j.healun.2019.12.002. Epub 2019 Dec 31. J Heart Lung Transplant. 2020. PMID: 31952977 Free PMC article.

Elevated NEDD9 correlated with PVR in idiopathic PAH (rho = 0.42, p < 0.0001, n = 54), connective tissue disease (CTD)-PAH (rho = 0.53, p < 0.0001, n = 53), and congenital heart disease-PAH (rho = 0.68, p < 0.0001, n = 10). In CTD-PAH, NEDD9 correlat

…

Elevated NEDD9 correlated with PVR in idiopathic PAH (rho = 0.42, p < 0.0001, n = 54), connective tissue disease (CTD)-PAH (rho =

…
36 results